SANUWAVE Health Inc
OTC:SNWV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SANUWAVE Health Inc
OTC:SNWV
|
US |
|
N
|
Next Generation Management Corp
OTC:NGMC
|
US |
|
TransAlta Corp
TSX:TA
|
CA |
|
TKO Group Holdings Inc
NYSE:TKO
|
US |
|
Competent Automobiles Company Ltd
BSE:531041
|
IN |
|
S
|
Superdry PLC
SWB:49S
|
UK |
|
South Plains Financial Inc
NASDAQ:SPFI
|
US |
|
Victoria PLC
LSE:VCP
|
UK |
SANUWAVE Health Inc
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. The company is headquartered in Suwanee, Georgia and currently employs 43 full-time employees. The company went IPO on 2008-11-07. The firm's is focused on regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The firm's lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. The company intends to apply its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions.
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. The company is headquartered in Suwanee, Georgia and currently employs 43 full-time employees. The company went IPO on 2008-11-07. The firm's is focused on regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The firm's lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. The company intends to apply its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions.
Record quarter: SANUWAVE said Q4 revenue hit an all-time high of $13.4 million, up 30% year over year, with adjusted EBITDA of $4.8 million, up from $3.7 million last year.
Full-year growth: 2025 revenue rose 35% to $44.1 million, and full-year adjusted EBITDA increased 89% to $13.6 million.
Wound care disruption: Management said CMS reimbursement changes and audits in the skin substitute market are pressuring many customers, reducing customer counts and slowing growth, but they believe the market is beginning to stabilize.
Channel shift: The company is expanding reseller and stocking distributor relationships to move faster into newly available market share; 32% of Q4 revenue came through outside resellers and distributors.
Guidance: SANUWAVE guided Q1 revenue to $9.6 million to $10.3 million and gave a preliminary 2025 revenue growth estimate of 16% to 25% versus 2024.
Product and supply: Gross margin was hurt in Q4 by a $486,000 write-off tied to sunsetting the PACE product line, while management said lower applicator pricing should help margins over time.
Customer activity: The company said it ended Q4 with 1,292 active systems, up 5% from Q3 on the new methodology, but also removed 168 systems as discontinued during the quarter.
